NCT03730142View on ClinicalTrials.gov

A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

July 25, 2020

Study Completion Date

July 25, 2020

Conditions
Advanced Cancer
Interventions
DRUG

WXFL10030390

WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.

Trial Locations (1)

Unknown

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY

NCT03730142 - A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter